Cytokine gene therapy of cancer using interleukin-12: Murine and clinical trials

Annals of the New York Academy of Sciences

Volumn 795, Issue , 1996, Pages 440-454

  Lotze, Michael T ^a,b   Zitvogel, Laurence ^a   Campbell, Ronna ^a   Robbins, Paul D ^a   Elder, Elaine ^a   Haluszczak, Cathy ^a   Martin, Dina ^a   Whiteside, Theresa L ^a   Storkus, Walter J ^a   Tahara, Hideaki ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RECOMBINANT INTERLEUKIN 12;

ANTINEOPLASTIC ACTIVITY; BLOOD DISEASE; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DENDRITIC CELL; EXPRESSION VECTOR; FATIGUE; FEVER; FIBROBLAST; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEADACHE; HEMATOPOIESIS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; LYMPHOKINE ACTIVATED KILLER CELL; MYALGIA; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMID; RISK; TUMOR GROWTH; TUMOR REGRESSION;

EID: 17144451105     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb52715.x     Document Type: Conference Paper

References (41)

1. BUBENIK, J., P. PERLMAN, M. INDROVA, J. SIMOVA, T. JANDOVA & J. NEUWIR. 1983. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2) containing preparations. Cancer Immunol. Immunother. 14: 205.
2. FORNI, G., M. GIOVARELLI & A. SANTONI. 1985. Lymphokine activated tumor inhibition in vivo: 1. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J. Immunol. 134: 1305.
3. NASTALA, C. L., H. D. EDINOTON, W. J. STORKUS & M. T. LOTZE. 1993. Recombinant interleukin-12 (r-mIL-12) mediates regression of both subcutaneous and metastatic murine tumors. Surg. Forum 44: 518-521.
4. FEARON, E. R., D. M. PARDOL, T. ITAYA, P. GOLUMBEK, H. I. LEVITSKY, J. W. SIMONS, H. KARASUYAMA, B. VOGELSTEIN & P. FROST. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-400.
5. RUSSEL, S. J., C. FLEMMING, S. A. ECCLES, C. JOHNSON & M. K. L. COLLINS. 1990. Transfer in and expression of the human IL-2 gene in a transplantable rat sarcoma. In Cellular Immunology and the Immunotherapy of Cancer. M. T. Lotze & O. J. Finn, Eds.: 275-278. A. J. Liss and Co. New York.
6. GANSBACHER, B., K. ZIER, B. DANIELS, K. CRONIN, R. BANNERJI & E. GILBOA. 1990. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172: 1217-1224.
7. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J. Immunol. 149: 3627-3635.
8. KIM, T. S., S. J. RUSSELL, M. K. L. COLLINS & E. COHEN. 1992. Immunity to B16 melanoma in mice immunized with IL-2 secreting allogeneic mouse fibroblasts expressing melanoma associated antigens. Int. J. Cancer 51: 1-7.
9. PATEL, P. M., C. L. FLEMMING, S. J. RUSSELL, I. A. MCKAY, K. A. MACLENNAN, G. M. BOX, S. A. ECCLES & M. K. L. COLLINS. 1993. Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumour. Br. J. Cancer 68: 295-302.
10. CAVALLO, F., F. DIPIERRO, M. GIOVARELLI, A. GULINO, A. VACCA, A. STOPPAC-CIARO, M. FORNI, A. MODESTI & G. FORNI. 1993. Protective and curative potential of vaccination with interleukin-2 gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 53: 5067-5070.
11. + T cell-dependent tumor rejection. J. Exp. Med. 174: 1291-1298.
12. GANSBACHER, B., R. BANNERJI, B. DANIELS, K. ZIER, K. CRONIN & ELI GILBOA. 1990. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50: 7820-7825.
13. MIYATAKE, S., K. NISHIHARA, H. KIKUCHI, J. YAMASHITA, Y. NAMBA, M. HANAOKA & Y. WATANABE. 1990. Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with interferon-γ gene. J. Natl. Cancer Inst. 82: 217-220.
14. TEPPER, R. I., P. K. PATTENGALE & P. LEDER. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503-512.
15. GOLUMBEK, P. T., A. J. LAZENBY, H. I. LEVITSKY, L. M. JAFFEE, H. KARASUYAMA, M. BAKER & D. M. PARDOLL. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713-716.
16. ASHER, A. L., J. J. MULE, A. KASID, N. P. RESTIFO, J. C. SALO, C. M. REICHERT, G. JAFFE, B. FENDLY, M. KRIEGLER & S. A. ROSENBERG. 1991. Murine tumor cells transduced with the gene for tumor necrosis factor-α. J. Immunol. 146: 3227-3234.
17. BLANKENSTEIN, T., Z. QIN, K. UBERLA, W. MULLER, H. ROSEN, H.-D. VOLK & T. DIAMANTSTEIN. 1991. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene factor. J. Exp. Med. 173: 1047-1052.
18. COLOMBO, M. P., G. FERRARI, A. STOPPACCIARO, M. PARENZA, M. RODOLFO, F. MAVILIO & G. PARMIANI. 1991. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173: 889-897.
19. 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 87: 1486-1490.
20. KOBAYASHI, M., L. FITZ, M. RYAN, R. M. HEWICK, S. C. CLARK, S. CHANG, R. LOUDON, F. SHERMAN, B. PERUSSIA & G. TRINCIIIERI. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170: 827-845.
21. STERN, A. S., F. J. PODLASKI, J. D. HULMES, Y. C. E. PAN, P. M. QUINN, A. G. WOLITZKY, P. C. FAMILLETTI, D. L. STREMLO, T. TRUITT, R. CHIZZONITE & M. K. GATELY. 1990. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 87: 6808-6812.
22. WOLF, S. F., P. A. TEMPLE, M. KOBAYASHI, D. YOUNG, M. DICIG, L. LOWE, R. DZIALO, L. FITZ, C. FERENZ, R. M. HEWICK, K. KELLEHER, S. H. HERRMANN, S. C. CLARK, L. AZZONI, S. H. CHAN, G. TRINCHIERI & B. PERUSSIA. 1991. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol. 146: 3074-3081.
23. GUBLER, U., A. O. CHUA, D. S. SCHOENHAUT, C. M. DWYER, W. MCCOMAS, R. MOTYKA, N. NABAVI, A. G. WOLITZKY, P. M. QUINN, P. C. FAMILLETTI & M. K. GATELY. 1991. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA 88: 4143-4147.
24. WONG, H. L., D. E. WILSON, J. C. JENSON, P. C. FAMILLETTI, D. L. STREMLO & M. GATELY. 1988. Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell. Immunol. 111: 3-54.
25. CHAN, S. H., B. PERUSSIA, J. W. GUPTA, M. KOBAYASHI, M. POSPISIL, H. A. YOUNG, S. F. WOLF, D. YOUNG, S. C. CLARK & G. TRINCHIERI. 1991. Induction of interferon-γ production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173: 869-879.
26. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549.
27. GATELY, M. K., R. R. WARRIER, S. HONASOGE, D. A. FAHERTY, S. E. CONNAUGHTON, T. D. ANDERSON, U. SARMIENTO, B. R. HUBBARD & M. MURPHY. 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of INF-γ in vivo. Int. Immunol. 6: 157.
28. ALFONSO, C. C., T. M. SCHARTON, L. Q. VIEIRA, M. WYSOCKA, G. TRINCHIERI & P. SCOTT. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science (Washington, DC) 263: 235-237.
29. TAHARA, H., H. ZEH, G. M. MUELLER, M. K. GATELY, U. GUBLER, S. F. WOLFE, P. D. ROBBINS & M. T. LOTZE. 1992. Cancer vaccination using interleukin-12 (IL-12) gene transfer. Cold Spring Harbor Laboratory Meeting on Gene Therapy Abstract, 112. Cold Spring Harbor, NY.
30. TAHARA, H., H. J. Z. ZEH III, W. J. STORKUS, I. PAPPO, S. C. WATKINS, U. GUBLER, S. F. WOLF, P. D. ROBBINS & M. T. LOTZE. 1994. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce anti-tumor immunity to a murine melanoma in vivo. Cancer Res. 54: 182-189.
31. NASTALA, C. L., H. EDINGTON, W. STORKUS, T. G. MCKINNEY, H. TAHARA, M. J. BRUNDA, M. K. GATELY, R. SCHREIBER & M. T. LOTZE. 1994. Recombinant interleukin-12 administration induces tumor regression in association with interferon-gamma and nitric oxide production. J. Immunol. 153: 16.
32. BRUNDA, M. J., L. LUISTRO, R. R. WARRIER, R. B. WRIGHT, B. R. HUBBARD, K. MURPHY, S. F. WOLF & M. K. GATELY. 1993. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med. 178: 1223-1230.
33. NASTALA, C. L., H. D. EDINGTON, W. J. STORKUS & M. T. LOTZE. 1993. Recombinant interleukin-12 (rmIL-12) mediates regression of both subcutaneous and metastatic murine tumors. Surg. Forum 44: 518-521.
34. NASTALA, C. L., B. A. MCKINNEY, H. D. EDINGTON, H. TAHARA, M. K. GATELY, W. J. STORKUS & M. T. LOTZE. 1994. Interleukin-12 (IL-12) induces specific antitumor immunity in animals bearing established subcutaneous murine sarcoma. Surg. Forum 80: 492-494.
35. TAHARA, H., L. ZITVOGEL, W. J. STORKUS, H. J. ZEH III, T. G. MCKINNEY, R. D. SCHREIBER, U. GUBLER, P. D. ROBBINS & M. T. LOTZE. Effective eradication of established murine tumors with interleukin 12 (IL-12) gene therapy using a polycistronic retroviral vector. J. Immunol. 154: 6466-6474.
36. TAHARA, H. & M.T. LOTZE. 1995. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum. Gene Ther. 6: 1607-1624.
37. ATKINS, M. B., M. J. ROBERTSON, M. GORDON, M. T. LOTZE, M. DECOSTE, J. S. DUBOIS, J. RITZ, A. B. SANDLER, H. D. EDINGTON, P. D. GARZONE, J. W. MIER, C. M. CANNING, L. BATTIATO, H. TAHARA & M. L. SHERMAN. Phase I evaluation of intravenous recombinant human interleukin-12 (rhIL-12) in patients with advanced malignancies. Clin. Cancer Res. Submitted.
38. ZITVOGEL, L., H. TAHARA, P. D. ROBBINS, W. J. STORKUS, M. R. CLARKE, M. A. NALESNIK & M. T. LOTZE. 1995. Cancer immunotherapy of established tumors with interleukin-12: Effective delivery by genetically engineered fibroblasts. J. Immunol. 155: 1393-1403.
39. ELDER, E. M., M. T. LOTZE & T. L. WHITESIDE. 1996. Successful culture of cytokine gene-modified human dermal fibroblasts for biologic therapy of patients with cancer. Hum. Gene Ther. 7: 479-487.
40. ARMANT, M., R. ARMITAGE, N. BOIANI, G. DELESPESSE & M. SARFATI. 1996. Functional CD40 ligand expression on T lymphocytes in the absence of T cell receptor engagement: Involvement in interleukin-2-induced interleukin-12 and interferon-γ production. Eur. J. Immunol. 26: 1430-1434.
41. PENG, X., A. KASRAN, P. A. M. WARMERDAM, M. DEBOER & J. L. CEUPPENS. 1996. Accessory signaling by CD40 for T cell activation: Induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-γ production. Eur. J. Immunol. 26: 1621-1627.